Cairo University
Giza, Egypt
Location contact
Amira Nagy Abdellatif, PhD
CONTACT
Wafaa AM Abdelraouf Mohamed, B.Sc.
CONTACT
NCT Number: NCT06803173
This study will be conducted to assess the pelvic floor muscle (PFM) activity in primary dysmenorrhea (PD).
Trial opening soon.
Get Notified19 year–24 year
Female
Observational
Giza, Egypt
Amira Nagy Abdellatif, PhD
CONTACT
Wafaa AM Abdelraouf Mohamed, B.Sc.
CONTACT
Dysmenorrhea, marked by painful menstrual cramps, often involves increased PFM tension, spasms, and inflammation, affecting females' quality of life and productivity. The traditional focus has been on investigating the abdominal region in women with PD. However, this new perspective considers that the hormonal changes experienced during the menstrual cycle in PD patients may lead to a heightened sensitivity of the PFM, not just the abdominal area. This suggests that the pain associated with PD may have a more widespread impact on the pelvic region rather than being localized to the abdomen. Pelvic floor myofascial trigger points (MTrPs) may also exacerbate menstrual pain through the neural pathway.
There is a critical gap in the literature regarding the nature of the association between dysmenorrhea and PFM activity in this population. Yet, it is unknown whether the pain is a cause or result of increased PFM tone, and the nature of the association between menstrual pain and PFM tone in women with PD is also unknown.
So, this study utilizes transabdominal ultrasound (TAU) to examine PFM activity in PD, aiming to clarify how PFM activity contributes to menstrual pain. Understanding these dynamics could lead to preventive strategies and educational efforts highlighting the role of pelvic floor interventions in managing dysmenorrhea, potentially improving treatment methods and overall women's health management.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention
Time frame: 1 month
Transabdominal ultrasound (TAU) will be used to assess PFM contraction for all females ("cutting off the flow of urine mid-stream") in the three groups.
Time frame: 1 month
Transabdominal ultrasound (TAU) will be used to assess PFM relaxation during inspiration for all females.
Time frame: 1 month
It will be used to assess the bladder symptoms of pelvic floor dysfunction for all females in the three groups. This section will be scored 0-45, with higher scores meaning more dysfunction
Time frame: 1 month
It will be used to assess the bowel symptoms of pelvic floor dysfunction for all females in the three groups. This section will be scored 0-34, with higher scores meaning more dysfunction
Time frame: 1 month
The SF-36 questionnaire is a self-administered questionnaire containing 36 items. It measures health across eight multi-item dimensions, covering functional status, well-being, and overall health evaluation, each associated with 2-10 possible answers. The response to each question is extrapolated to a standardized set of answers, and the results are transferred to a scale of 0-100, where 0 represents the worst state of health and 100 represents the best state of health measured
Contact information is provided by the study sponsor or research team.
Cairo University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07658859
Primary Dysmenorrhea
View Trial DetailsNCT07176780
Dysmenorrhea, Menstrual Cramps
View Trial DetailsNCT07529561
Menstural Cramps, Primary Dysmenorrhea
Nellore, Andhra Pradesh, India
View Trial DetailsNCT07376759
Menstruation Disturbances, Pathologic Processes
View Trial Details